Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2023

Traitement au bimékizumab chez les patients atteints de spondylarthrite axiale active: efficacité et innocuité à 52 semaines des études randomisées et parallèles de phase 3 BE MOBILE 1 et BE MOBILE 2

Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803

Xu H,

Vaux T,

Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.

Keywords:

October 2023

Efficacité et sécurité de l'Upadacitinib chez les patients atteints de spondylarthrite ankylosante réfractaire aux traitements biologiques : résultats à un an de l'extension ouverte d'une étude de phase III

Arthritis Res Ther 2023; 2023;18;25(1):172 doi 10.1186/s13075-023-03128-1

Inman R,

Li Y,

Bu X,

Shmagel A,

Wung P,

Song I,

Deodhar A

The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.

Keywords:

September 2023

Différences et similitudes entre les recommandations EULAR/ASAS-EULAR et les recommandations nationales pour le traitement des patients atteints de rhumatisme psoriasique et de spondylarthrite axiale en Europe

Lancet Reg Health Eur. 2023;33:100706 doi: 10.1016/j.lanepe.2023.100706

Laas K,

Rotar Z,

Castrejón Fernández I,

Loft AG,

Comparing the alignment of European national recommendations for patients with PsA and axSpA with EULAR and ASAS-EULAR treatment recommendations found that only a minority of national treatment recommendations were completely aligned.

Keywords:

ASAS-EULAR

July 2023

Effet du golimumab en intraveineuse sur la fatigue et relation avec la réponse clinique chez les adultes atteints de spondylarthrite ankylosante active dans l'étude de phase 3 GO-ALIVE

Rheumatol Ther. 2023;10(4):983–999 doi 10.1007/s40744-023-00556-y

Deodhar A,

Shiff NJ,

Gong C,

Chan EK,

Hsia EC,

Lo KH,

Akawung A,

Kim L,

Xu S,

Reveille JD

Administration of IV-golimumab 2 mg/kg improves fatigue symptoms in axial spondylitis in a 52 Week study. At Week 16 of treatment, improvements in ASAS, ASDAS, BASDAI and SF-36 scores were observed at week 16 of treatment.

Keywords:

March 2023

Association Between Baseline Cardiovascular Risk and Incidence Rates of Major Adverse Cardiovascular Events and Malignancies in Patients with Psoriatic Arthritis and Psoriasis Receiving Tofacitinib

Ther Adv Musculoskelet Dis. 2023 doi: 10.1177/1759720X221149965

Jo H,

Kwok K,

Baseline 10-year atherosclerotic cardiovascular disease risk and metabolic syndrome are potentially associated with the incidence of both MACE and malignancies in patients receiving TOFA in the PsA and PsO clinical trial programs. This post hoc analysis aimed to examine the baseline CV disease risk and its association with the occurrence of MACE and malignancies in TOFA-treated patients with PsA and PsO.

Keywords:

Low Rates of Radiographic Progression Associated with Clinical Efficacy Following up to 2 Years of Treatment with Guselkumab: Results From a Phase 3, Randomised, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis

RMD Open. 2023 doi: 10.1136/rmdopen-2022-002789

Xu XL,

Jiang Y,

Sheng S,

Shawi M,

Chakravarty SD,

Lavie F,

Mease PJ

Data from this paper provides a robust analysis of radiographic progression through 2 years in a phase 3 study of guselkumab in patients with PsA. This study sought to evaluate the relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with PsA receiving up to 2 years of guselkumab therapy in DISCOVER-2.